{"id":3566,"date":"2018-11-12T16:58:39","date_gmt":"2018-11-12T11:28:39","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3566"},"modified":"2025-05-06T14:52:54","modified_gmt":"2025-05-06T09:22:54","slug":"virus-the-cancer-therapy-of-the-future","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/virus-the-cancer-therapy-of-the-future","title":{"rendered":"Virus, the Cancer Therapy of the Future"},"content":{"rendered":"

Could a virus<\/strong> be a treatment therapy? Confusing, isn’t it? On the face value, it seems no; but on delving deeper, the confusion dissipates. There have been tireless efforts among a section of scientists to convert certain viruses through biotechnology techniques into anti-disease agents to infect and destroy cancer cells. This mode of treatment is called Virotherapy<\/strong>.<\/p>\n

It is needless to mention that cancer<\/strong> is one of the most dreaded diseases that claim millions of people\u2019s lives worldwide every year. In a World Health Organization (WHO)<\/strong> publication, cancer will cause at least 9 million<\/strong> deaths across the world in 2018<\/strong>. Cancer is the second most potential cause of death globally, WHO claims. In a worldwide scale, around 18 million<\/strong> new cancer cases will be diagnosed in 2018<\/strong>; and the number of diagnosed cases will increase past 23 million<\/strong> by 2030<\/strong>, as per WHO in its publication.<\/p>\n

In the latest quest for an effective cancer therapy, researchers have zeroed upon the Seneca Valley Virus<\/strong> (SVV), which is regarded as the next breakthrough wave in cancer treatment. Researchers at the Okinawa Institute of Science and Technology Graduate University<\/strong> in Japan and the University of Otago<\/strong> in Dunedin of New Zealand have described how the virus could be turned into oncolytic viruses<\/a><\/strong> (or the anti-cancer agents).<\/p>\n

To elicit the behavioural pattern of the cancer particles, scientists have studied numerous images of the particles captured through cryogenic-electron microscopy<\/strong>. Holistic understanding of the structure of the particles is the key to the creation of an effective virus that can kill cancer cells. SVV has a peculiar characteristic. It targets a specific receptor\u2014the anthrax toxin receptor 1 (ANTXR1)<\/strong>, which is present only in tumours. Interestingly, the cousin of the receptor– ANTXR2<\/strong>\u2014resides only in healthy tissues. SVV binds only to the receptor in tumours but not to the one in healthy tumours, and that could make the virus a potential therapy for many cancer types as the ANTXR1 receptor is present on the tumour cells of over 60 percent of human cancers.<\/p>\n

In the early phase, clinical trials involving pediatric solid tumours and small-cell lung cancer<\/a>, the virus has exhibited substantial cancer-fighting qualities, which make it a potential cancer therapy in the future.<\/p>\n","protected":false},"excerpt":{"rendered":"

Could a virus be a treatment therapy? Confusing, isn’t it? On the face value, it seems no; but on delving deeper, the confusion dissipates. There have been tireless efforts among a section of scientists to convert certain viruses through biotechnology techniques into anti-disease agents to infect and destroy cancer cells. This mode of treatment is […]<\/p>\n","protected":false},"author":1,"featured_media":3570,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[2130,2134,2129,2131,2133,2135,985,903,2127,345,395,1497,2128,2132,2019,2136],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-3566","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-alopecia-drug","tag-aminopeptidase-a","tag-concert-pharmaceuticals","tag-ctp-543","tag-firibastat","tag-georgia-institute-of-technology","tag-glaxosmithkline","tag-gsk","tag-gsk095","tag-keytruda","tag-merck","tag-multiple-sclerosis","tag-pd1-checkpoint-inhibitor","tag-quantum-genomics","tag-rheumatoid-arthritis","tag-thymocytes","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nVirus, the Cancer Therapy of the Future - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"A section of scientists to convert certain viruses through biotechnology techniques into anti-disease agents to infect and destroy cancer cells......\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/virus-the-cancer-therapy-of-the-future\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Virus, the Cancer Therapy of the Future - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"A section of scientists to convert certain viruses through biotechnology techniques into anti-disease agents to infect and destroy cancer cells......\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/virus-the-cancer-therapy-of-the-future\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-12T11:28:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-06T09:22:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/10180054\/10-blog-viruses-FB.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Virus, the Cancer Therapy of the Future - DelveInsight Business Research","description":"A section of scientists to convert certain viruses through biotechnology techniques into anti-disease agents to infect and destroy cancer cells......","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/virus-the-cancer-therapy-of-the-future","og_locale":"en_US","og_type":"article","og_title":"Virus, the Cancer Therapy of the Future - DelveInsight Business Research","og_description":"A section of scientists to convert certain viruses through biotechnology techniques into anti-disease agents to infect and destroy cancer cells......","og_url":"https:\/\/www.delveinsight.com\/blog\/virus-the-cancer-therapy-of-the-future","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-11-12T11:28:39+00:00","article_modified_time":"2025-05-06T09:22:54+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/10180054\/10-blog-viruses-FB.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/virus-the-cancer-therapy-of-the-future","url":"https:\/\/www.delveinsight.com\/blog\/virus-the-cancer-therapy-of-the-future","name":"Virus, the Cancer Therapy of the Future - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/virus-the-cancer-therapy-of-the-future#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/virus-the-cancer-therapy-of-the-future#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/10180054\/10-blog-viruses-FB.jpg","datePublished":"2018-11-12T11:28:39+00:00","dateModified":"2025-05-06T09:22:54+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"A section of scientists to convert certain viruses through biotechnology techniques into anti-disease agents to infect and destroy cancer cells......","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/virus-the-cancer-therapy-of-the-future"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/virus-the-cancer-therapy-of-the-future#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/10180054\/10-blog-viruses-FB.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/10180054\/10-blog-viruses-FB.jpg","width":1200,"height":630},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/10180054\/10-blog-viruses-FB-300x158.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">alopecia drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">aminopeptidase A<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Concert Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">CTP-543<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">firibastat<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Georgia Institute of Technology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">GSK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">GSK095<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Keytruda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Multiple Sclerosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">PD1 checkpoint inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Quantum Genomics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">rheumatoid arthritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">thymocytes<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">alopecia drug<\/span>","<span class=\"advgb-post-tax-term\">aminopeptidase A<\/span>","<span class=\"advgb-post-tax-term\">Concert Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">CTP-543<\/span>","<span class=\"advgb-post-tax-term\">firibastat<\/span>","<span class=\"advgb-post-tax-term\">Georgia Institute of Technology<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">GSK<\/span>","<span class=\"advgb-post-tax-term\">GSK095<\/span>","<span class=\"advgb-post-tax-term\">Keytruda<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Multiple Sclerosis<\/span>","<span class=\"advgb-post-tax-term\">PD1 checkpoint inhibitor<\/span>","<span class=\"advgb-post-tax-term\">Quantum Genomics<\/span>","<span class=\"advgb-post-tax-term\">rheumatoid arthritis<\/span>","<span class=\"advgb-post-tax-term\">thymocytes<\/span>"]}},"comment_count":"1","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Nov 12, 2018","modified":"Updated on May 6, 2025"},"absolute_dates_time":{"created":"Posted on Nov 12, 2018 4:58 pm","modified":"Updated on May 6, 2025 2:52 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3566"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3566\/revisions"}],"predecessor-version":[{"id":31742,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3566\/revisions\/31742"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3570"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3566"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3566"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}